From a CRISPR therapy's FDA priority review to oral HAE prophylaxis data and a needle-free epinephrine resubmission, 4 allergy stories from September.
News|Articles|November 4, 2025
6 Allergy Headlines You Missed in October 2025
Author(s)Chelsie Derman
This month in review spotlights 6 top allergy stories, from falling peanut allergy rates to intranasal steroid cream easing post-surgical rhinosinusitis.
Advertisement
Advertisement
This November, breakthroughs in allergy research are capturing attention across prevention, oral immunotherapy, and chronic rhinosinusitis management. Real-world data show declining peanut allergy rates linked to early introduction guidelines, while low-dose peanut OIT offers effective desensitization with fewer reactions. Early formula feeding in newborns also emerged as a potential risk factor for food allergies.
Related to this article
DBV has requested priority review for the epicutaneous patch, supported by phase 3 VITESSE data showing a 31.8-point responder rate gain vs placebo.
Remibrutinib doubled complete Total Fric Score response vs placebo at week 12 in RemIND, becoming the first therapy approved specifically for SD.
Florence Schleich, MD, PhD, explains how exacerbation phenotypes and useful biomarkers shift across anti-IL-5, anti-IL-5R, and anti-TSLP therapies.
Physicians and patients cited perceived mild severity as the top reason for leaving HAE attacks untreated in a recent Adelphi survey.
Ryaltris pediatric approval, lonvo-z and deucrictibant HAE filings, PVX108 Fast Track, and Palforzia's exit headline Q3 2026 allergy news.
The Liver Keeps the Score: Americans Are Drinking Less, but Alcohol-Associated Liver Disease May Lag
Drinking fell for the first time since COVID-19, but not for adults 50 to 64. Hepatologists explain what clinicians can do to close the gap.
As drinking declines, Stevan Gonzalez, MD, Frances Lee, MD, and Brian Lee, MD, on the lingering burden of alcohol-associated liver disease.
Advertisement
Advertisement